TrialJournal of diabetes investigation2026

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study.

Leili Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.